Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia
Objectives To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.Methods In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy fo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2460726 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687536832610304 |
|---|---|
| author | Tian Xu Yilin Ruan Na Liu Yi Wang Xiujuan Zang Yuhua Ma Hualin Qi Xiuhua Mi Geping Yu Chunyan Zhang Xiaomin Huang Jingyuan Xie Nan Chen Hong Ren |
| author_facet | Tian Xu Yilin Ruan Na Liu Yi Wang Xiujuan Zang Yuhua Ma Hualin Qi Xiuhua Mi Geping Yu Chunyan Zhang Xiaomin Huang Jingyuan Xie Nan Chen Hong Ren |
| author_sort | Tian Xu |
| collection | DOAJ |
| description | Objectives To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.Methods In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.Results At start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks, p > 0.05), but there was no significant difference in hemoglobin change between the two groups over the course of observation (p = 0.185). At the early stage of the study (12 weeks), the transferrin saturation (TSAT) of roxadustat group decreased significantly from the baseline (32.7 (20.6) vs. 22.1 (18.7)%, p = 0.001). At the end of the study period (48 weeks), total cholesterol (3.89 ± 0.92 vs. 4.52 ± 1.14 mmol/L, p = 0.012), low density lipoprotein cholesterol (2.24 ± 0.74 vs. 2.63 ± 0.82 mmol/L, p = 0.045) and triglyceride (1.35 (0.86) vs. 1.89 (1.27) mmol/l, p = 0.013) in roxadustat group were significantly lower than those in EPO group.Conclusions Roxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO. |
| format | Article |
| id | doaj-art-a54a446700744e20a5a64d2a09cdbee2 |
| institution | DOAJ |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-a54a446700744e20a5a64d2a09cdbee22025-08-20T03:22:18ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492025-12-0147110.1080/0886022X.2025.2460726Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemiaTian Xu0Yilin Ruan1Na Liu2Yi Wang3Xiujuan Zang4Yuhua Ma5Hualin Qi6Xiuhua Mi7Geping Yu8Chunyan Zhang9Xiaomin Huang10Jingyuan Xie11Nan Chen12Hong Ren13Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai Songjiang District Central Hospital, Shanghai, ChinaDepartment of Nephrology, Traditional Chinese Medicine Hospital of Kunshan, Kunshan, Jiangsu, ChinaDepartment of Nephrology, The People’s Hospital of Pudong New District in Shanghai, Shanghai, ChinaDepartment of Nephrology, Shanghai Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, ChinaDepartment of Nephrology, Tonglu First People’s Hospital, Tonglu, Hangzhou, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaObjectives To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.Methods In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.Results At start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks, p > 0.05), but there was no significant difference in hemoglobin change between the two groups over the course of observation (p = 0.185). At the early stage of the study (12 weeks), the transferrin saturation (TSAT) of roxadustat group decreased significantly from the baseline (32.7 (20.6) vs. 22.1 (18.7)%, p = 0.001). At the end of the study period (48 weeks), total cholesterol (3.89 ± 0.92 vs. 4.52 ± 1.14 mmol/L, p = 0.012), low density lipoprotein cholesterol (2.24 ± 0.74 vs. 2.63 ± 0.82 mmol/L, p = 0.045) and triglyceride (1.35 (0.86) vs. 1.89 (1.27) mmol/l, p = 0.013) in roxadustat group were significantly lower than those in EPO group.Conclusions Roxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO.https://www.tandfonline.com/doi/10.1080/0886022X.2025.2460726Roxadustatblood lipidsperitoneal dialysisanemiairon metabolism |
| spellingShingle | Tian Xu Yilin Ruan Na Liu Yi Wang Xiujuan Zang Yuhua Ma Hualin Qi Xiuhua Mi Geping Yu Chunyan Zhang Xiaomin Huang Jingyuan Xie Nan Chen Hong Ren Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia Renal Failure Roxadustat blood lipids peritoneal dialysis anemia iron metabolism |
| title | Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia |
| title_full | Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia |
| title_fullStr | Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia |
| title_full_unstemmed | Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia |
| title_short | Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia |
| title_sort | effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia |
| topic | Roxadustat blood lipids peritoneal dialysis anemia iron metabolism |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2460726 |
| work_keys_str_mv | AT tianxu effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT yilinruan effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT naliu effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT yiwang effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT xiujuanzang effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT yuhuama effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT hualinqi effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT xiuhuami effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT gepingyu effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT chunyanzhang effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT xiaominhuang effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT jingyuanxie effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT nanchen effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia AT hongren effectofroxadustatonloweringbloodlipidsinperitonealdialysispatientswithanemia |